At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
The move strengthens GBL’s clinical-stage presence in the United States
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
India plays a critical role in Bristol Myers Squibb’s global strategy
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
This launch is part of the company's strategy to expand its nutraceutical portfolio
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Zylet Ophthalmic Suspension, 0.5%/0.3%, of Bausch & Lomb
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
The multi-partner team will integrate new technologies across the entire mAb production workflow, from cell line development to purification
The cobas Mass Spec solution Ionify reagent portfolio now covers therapeutic drug monitoring for immunosuppressants and antibiotics
Subscribe To Our Newsletter & Stay Updated
